

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number  
**WO 03/051872 A1**

(51) International Patent Classification<sup>7</sup>: C07D 417/12, A61P 25/00

(74) Agent: LAWRENCE, Geoffrey, Mark, Prouse; Corporate Intellectual Property, GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(21) International Application Number: PCT/GB02/05665

(22) International Filing Date:  
13 December 2002 (13.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0130341.1 19 December 2001 (19.12.2001) GB

(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM P.L.C. [GB/GB]; 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COULTON, Steven [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW (GB). JOHNS, Amanda [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW (GB). PORTER, Roderick, Alan [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS

(57) Abstract: This invention relates to heterocyclic substituted ethylene diamine derivatives and their use as pharmaceuticals.

WO 03/051872 A1

## ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS

This invention relates to heterocyclic substituted ethylene diamine derivatives and their use as pharmaceuticals.

- 5 Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers.

Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 (HFGAN72), have been identified and are disclosed in EP-A-875565, EP-A-875566 and WO 96/34877. Polypeptides and polynucleotides encoding a second  
10 human orexin receptor, orexin-2 (HFGANP), have been identified and are disclosed in EP-A-893498.

Polypeptides and polynucleotides encoding polypeptides which are ligands for the orexin-1 receptor, e.g. orexin-A (Lig72A) are disclosed in EP-A-849361.

- Orexin receptors are found in the mammalian host and may be responsible for many  
15 biological functions, including pathologies including, but not limited to, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; severe mental retardation and dyskinesias such as Huntington's  
20 disease and Gilles de la Tourett's syndrome; disturbed biological and circadian rhythms; feeding disorders, such as anorexia, bulimia, cachexia, and obesity; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome / disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumor / adenoma; hypothalamic diseases; Froehlich's syndrome; adrenohypophysis disease; hypophysis disease;  
25 hypophysis tumor / adenoma; pituitary growth hormone; adrenohypophysis hypofunction; adrenohypophysis hyperfunction; hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; dwarfism; gigantism;  
30 acromegaly; sleep disturbances associated with such diseases as neurological disorders, neuropathic pain and restless leg syndrome, heart and lung diseases; acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischaemic or haemorrhagic stroke; subarachnoid haemorrhage; head injury such as sub-arachnoid haemorrhage associated with traumatic head injury; ulcers; allergies; benign prostatic hypertrophy;  
35 chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain, such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection, e.g. HIV, post-polio syndrome,

and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; nausea, vomiting; conditions associated with visceral pain including irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; sleep  
5 apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders, which includes nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration, epilepsy, and seizure disorders.

Experiments have shown that central administration of the ligand orexin-A (described in more detail below) stimulated food intake in freely-feeding rats during a 4 hour time period. This  
10 increase was approximately four-fold over control rats receiving vehicle. These data suggest that orexin-A may be an endogenous regulator of appetite. Therefore, antagonists of its receptor may be useful in the treatment of obesity and diabetes, see *Cell*, 1998, 92, 573-585.


There is a significant incidence of obesity in westernised societies. According to WHO definitions a mean of 35% of subjects in 39 studies were overweight and a further 22% clinically  
15 obese. It has been estimated that 5.7% of all healthcare costs in the USA are a consequence of obesity. About 85% of Type 2 diabetics are obese, and diet and exercise are of value in all diabetics. The incidence of diagnosed diabetes in westernised countries is typically 5% and there are estimated to be an equal number undiagnosed. The incidence of both diseases is rising, demonstrating the inadequacy of current treatments which may be either ineffective or have toxicity  
20 risks including cardiovascular effects. Treatment of diabetes with sulfonylureas or insulin can cause hypoglycaemia, whilst metformin causes GI side-effects. No drug treatment for Type 2 diabetes has been shown to reduce the long-term complications of the disease. Insulin sensitisers will be useful for many diabetics, however they do not have an anti-obesity effect.

Rat sleep/EEG studies have also shown that central administration of orexin-A, an agonist  
25 of the orexin receptors, causes a dose-related increase in arousal, largely at the expense of a reduction in paradoxical sleep and slow wave sleep 2, when administered at the onset of the normal sleep period. Therefore antagonists of its receptor may be useful in the treatment of sleep disorders including insomnia.

The present invention provides heterocyclic substituted ethylene diamine derivatives which  
30 are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors. In particular, these compounds are of potential use in the treatment of obesity, including obesity observed in Type 2 (non-insulin-dependent) diabetes patients, and/or sleep disorders, and/or stroke, particularly ischemic or haemorrhagic stroke, and/or for blocking the emetic response i.e. useful in the treatment of nausea and vomiting.

35 International Patent Applications WO99/09024, WO99/58533, WO00/47577, and WO00/47580, disclose phenyl urea derivatives and WO00/47576, discloses quinolinyl cinnamide derivatives as orexin receptor antagonists.

According to the invention there is provided compounds of formula (I):



(I)

wherein:

5 R represents an optionally substituted (C<sub>1-4</sub>)alkyl;

Y represents hydrogen or an optionally substituted (C<sub>1-4</sub>)alkyl;

Het represents an optionally substituted 5- or 6- membered heteroaryl group containing up to 3 heteroatoms selected from N, O, and S, or an optionally substituted bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S;

10 Ar represents a phenyl or a 5- or 6-membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R<sup>3</sup>, and further optional substituents; or Ar represents an optionally substituted bicyclic aromatic or heteroaromatic group containing up to 3 heteroatoms selected from N, O and S;

15 R<sup>3</sup> independently represents hydrogen, an optionally substituted (C<sub>1-4</sub>)alkoxy, halo, optionally substituted (C<sub>1-6</sub>)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 3 heteroatoms selected from N, O and S;

or pharmaceutically acceptable derivatives thereof, provided the compound is not

N-[2-(7-chloro-quinolin-4-ylamino)ethyl]-N-methyl-phthalamic acid or

N-methyl-n-[2-napthalen-2-ylaminoethyl]benzamide.

20 Examples of 5- or 6- membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl, isothiazolyl, isoxazolyl, pyrazinyl or pyrazolyl.

25 When Het represents a bicyclic heteroaryl it may be selected from isoquinolinyl, quinoxalinyl, benzoxazolyl, quinolinyl, naphthyridinyl, benzofuranyl, benzimidazolyl, benzothienyl, indolyl, benzothiazolyl or quinazolinyl.

Examples of where Ar represents an optionally substituted bicyclic aromatic or heteroaromatic include naphthyl, quinolinyl, naphthyridinyl, benzofuranyl, benzimidazolyl, benzoxazolyl, isoquinolinyl, quinoxalinyl or quinazolinyl.

30 Preferably R is optionally substituted methyl.

Preferably Het represents pyrimidinyl, benzoxazolyl or quinoxalinyl.

Preferably when Ar represents phenyl, or a 5- or 6- membered heteroaryl group the substituent R<sup>3</sup> is *ortho* to the amide carbonyl group.

35 Preferably Ar represents optionally substituted thiazolyl or pyrazolyl.

Examples of groups where  $R^3$  is a 5- or 6-membered heterocyclic ring containing up to 3 heteroatoms selected from N, O and S, include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, piperidine, piperazine, thiomorpholine or morpholine.

- 5 Preferably  $R^3$  represents trifluoromethoxy, methoxy, ethoxy, halo, or optionally substituted phenyl, pyridyl, pyrazolyl, pyrimidinyl or oxadiazolyl group.

Even more preferably  $R^3$  represents an optionally substituted phenyl, e.g. 4-fluorophenyl.

- Optional substituents for the groups Y, R,  $R^3$ , Ar and Het include halogen, hydroxy, oxo, cyano, nitro,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy, halo $(C_{1-4})$ alkyl, halo $(C_{1-4})$ alkoxy,  $(C_{1-4})$ acyl, aryl, aryl $(C_{1-4})$ alkyl, aryl $(C_{1-4})$ alkoxy,  $(C_{1-4})$ alkylthio,  $(C_{1-4})$ alkylamino $(C_{1-4})$ alkyl, hydroxy $(C_{1-4})$ alkyl, hydroxy $(C_{1-4})$ alkoxy,  $(C_{1-4})$ alkoxy $(C_{1-4})$ alkyl,  $(C_{3-6})$ cycloalkyl $(C_{1-4})$ alkoxy,  $(C_{1-4})$ alkanoyl,  $(C_{1-4})$ alkoxycarbonyl,  $(C_{1-4})$ alkylsulfonyl,  $(C_{1-4})$ alkylsulfonyloxy,  $(C_{1-4})$ alkylsulfonyl $(C_{1-4})$ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkylsulfonylamido,  $(C_{1-4})$ alkylamido,  $(C_{1-4})$ alkylsulfonylamido $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkylamido $(C_{1-4})$ alkyl, arylsulfonylamido, arylcarboxamido, arylsulfonylamido $(C_{1-4})$ alkyl, arylcarboxamido $(C_{1-4})$ alkyl, aroyl, aroyl $(C_{1-4})$ alkyl, or aryl $(C_{1-4})$ alkanoyl group; a group  $R^aR^bN$ -,  $R^aR^bN(CH_2)_n$ -,  $R^aR^bN(CH_2)_nO$ -,  $R^aOCO(CH_2)_n$ ,  $R^aCON(R^b)(CH_2)_n$ ,  $R^aR^bNCO(CH_2)_n$ ,  $R^aR^bNSO_2(CH_2)_n$ , or  $R^aSO_2NR^b(CH_2)_n$ , where each of  $R^a$  and  $R^b$  independently represents a hydrogen atom or a  $(C_{1-4})$ alkyl group or where appropriate  $R^aR^b$  forms part of a  $(C_{3-6})$ azacycloalkane or  $(C_{3-6})$ (2-oxo)azacycloalkane ring, n represents an integer from 1 to 4, and r represents zero or an integer from 1 to 4. Additionally when the substituent is  $R^aR^bN(CH_2)_n$ - or  $R^aR^bN(CH_2)_nO$ ,  $R^a$  with at least one  $CH_2$  of the  $(CH_2)_n$  portion of the group form a  $(C_{3-6})$ azacycloalkane and  $R^b$  represents hydrogen, a  $(C_{1-4})$ alkyl group or with the nitrogen to which it is attached forms a second fused  $(C_{3-6})$ azacycloalkane.

- 25 Preferred optional substituents for Ar are halogen, cyano,  $(C_{1-4})$ alkyl, hydroxy $(C_{1-4})$ alkyl,  $R^aR^bN(CH_2)_n$  or  $R^aR^bN$ .

Preferred optional substituents for Het are halogen, cyano,  $(C_{1-4})$ alkyl, hydroxy $(C_{1-4})$ alkyl,  $(C_{1-4})$ acyl,  $(C_{1-4})$ alkoxy $(C_{1-4})$ alkyl,  $R^aR^bNCO(CH_2)_n$ ,  $R^aR^bN(CH_2)_n$  or  $R^aR^bN$ .

Preferred optional substituents for  $R^3$  are halogen,  $R^aR^bN$  and  $R^aR^bN(CH_2)_nO$ .

- 30 In addition Het may be optionally substituted by a phenyl ring optionally substituted by a halogen, cyano, or  $C_{1-4}$ alkanoyl or  $C_{1-4}$ alkylsulfonyl group; or by a 5- or 6-membered heterocyclic ring, optionally substituted by a  $(C_{1-2})$ alkyl or  $R^aR^bN$ - group; wherein  $R^a$  and  $R^b$  are as defined above.

In the groups Ar and Het, substituents positioned *ortho* to one another may be linked to form a fused ring.

- 35 When a halogen atom is present in the compound of formula (I) it may be fluorine, chlorine, bromine or iodine.

When used herein the term aryl means a 5- or 6- membered ring, for example phenyl, or a 7- to 12- membered bicyclic ring system where at least one of the rings is aromatic, for example naphthyl.

5 When the compound of formula (I) contains an alkyl group, whether alone or forming part of a larger group, e.g. alkoxy or alkylthio, the alkyl group may be straight chain, branched or cyclic, or combinations thereof, it is preferably methyl or ethyl.

It will be appreciated that compounds of formula (I) may exist as *R* or *S* enantiomers. The present invention includes within its scope all such isomers, including mixtures. Where additional chiral centres are present in compounds of formula (I), the present invention includes within its  
10 scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

It will be understood that the invention includes pharmaceutically acceptable derivatives of compounds of formula (I) and that these are included within the scope of the invention.

15 Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable derivatives.

As used herein "pharmaceutically acceptable derivative" includes any pharmaceutically acceptable salt, ester or salt of such ester of a compound of formula (I) which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an  
20 active metabolite or residue thereof.


It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids e.g. succinic,  
25 maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I).

Certain of the compounds of formula (I) may form acid addition salts with one or more  
30 equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially  
35 at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.

According to a further feature of the invention there is provided a process for the preparation of compounds of formula (I) and salts thereof. The following schemes detail synthetic routes to compounds of the invention.

# 5    **Scheme 1**



Wherein Het, Ar, R and Y are as defined for formula (I), L<sup>1</sup> and L<sup>2</sup> are leaving groups, and P is a protecting group.

10

Reaction of (II) with HetL<sup>1</sup> proceeds in an inert solvent such as dimethylformamide, xylene or THF at ambient or elevated temperature. A base such as potassium carbonate or N,N-diisopropylethylamine may be used.

15

Examples of suitable leaving groups L<sup>1</sup> include chlorine, fluorine and triflate.

Examples of protecting groups P include *t*-butoxycarbonyl, trifluoroacetyl and benzyloxycarbonyl. Deprotection conditions are respectively, acid (e.g. trifluoroacetic acid in dichloromethane), base (e.g. sodium hydroxide in a solvent such as aqueous methanol) and catalytic hydrogenolysis in an inert solvent (e.g. using palladium on charcoal in a lower alcohol or ethyl acetate).


20

Examples of suitable leaving groups L<sup>2</sup> include halogen, OC(=O)alkyl and OC(=O)O-alkyl. The transformation (IV) to (I) may be carried out in an inert solvent such as dichloromethane, in the presence of a base such as triethylamine. Alternatively this step may be carried out when L<sup>2</sup> represents hydroxy, in which case reaction with (IV) takes place in an inert solvent such as dichloromethane in the presence of a diimide reagent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and an activator such as 1-hydroxybenzotriazole. Also where L<sup>2</sup> represents hydroxy the reaction can be effected using O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) with a base such as triethylamine or N,N-diisopropylethylamine.

25

30

Scheme 2



Wherein Het, Ar, R and Y are as defined for formula (I),  $\text{L}^1$  and  $\text{L}^2$  are leaving groups, and P is a  
 5 protecting group.

A compound of formula (VI) may be prepared by reacting a compound of formula (V) with an  
 aldehyde,  $\text{R}'\text{CHO}$ . Suitable reducing agents which may be employed include sodium borohydride,  
 sodium cyanoborohydride or sodium triacetoxyborohydride under acidic conditions, or catalytic  
 10 hydrogenation. The reaction may conveniently be effected in a solvent such as ethanol or  
 dichloroethane.

Examples of protecting groups P include *t*-butoxycarbonyl, trifluoroacetyl and  
 benzyloxycarbonyl. Deprotection conditions are respectively, acid (e.g. trifluoroacetic acid in  
 15 dichloromethane), base (e.g. sodium hydroxide in a solvent such as aqueous methanol) and catalytic  
 hydrogenolysis in an inert solvent (e.g. using palladium on charcoal in a lower alcohol or ethyl  
 acetate).

Reaction of (VIII) with  $\text{HetL}^1$  proceeds in an inert solvent such as dimethylformamide, xylene or  
 20 THF at ambient or elevated temperature. A base such as potassium carbonate or *N,N*-  
 diisopropylethylamine may be used.

Examples of suitable leaving groups  $\text{L}^1$  include chlorine, fluorine and triflate.



Examples of suitable leaving groups  $L^2$  include halogen,  $OC(=O)alkyl$  and  $OC(=O)O-alkyl$ . The transformation (III) to (I) may be carried out in an inert solvent such as dichloromethane, in the presence of a base such as triethylamine. Alternatively this step may be carried out when  $L^2$  represents hydroxy, in which case reaction with (III) takes place in an inert solvent such as dichloromethane in the presence of a diimide reagent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and an activator such as 1-hydroxybenzotriazole. Also where  $L^2$  represents hydroxy the reaction can be effected using O-(7-azabenzotriazol-1-yl)- $N,N,N',N'$ -tetramethyluronium hexafluorophosphate (HATU) with a base such as triethylamine or  $N,N$ -diisopropylethylamine.

Compounds of formula (II) and (V) are known in the literature or can be prepared by known methods

The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, e.g. 5 to 1000, preferably 10 to 100 compounds of formula (I). Compound libraries may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I), or pharmaceutically acceptable derivatives thereof.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are useful for the treatment of diseases or disorders where an antagonist of a human orexin receptor is required such as obesity and diabetes; prolactinoma; hypoprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; Cushing's syndrome/disease; hypothalamic-adrenal dysfunction; dwarfism; sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases; depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delirium; dementia; bulimia and hypopituitarism. The compounds of formula (I) or pharmaceutically acceptable derivatives thereof are also useful in the treatment of stroke, particularly ischaemic or haemorrhagic stroke. Furthermore the compounds of formula (I) or pharmaceutically acceptable derivatives thereof are also useful in blocking the emetic response.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are particularly useful for the treatment of obesity, including obesity associated with Type 2 diabetes, sleep disorders, stroke and blocking the emetic response for example nausea and vomiting.

Other diseases or disorders which may be treated in accordance with the invention include disturbed biological and circadian rhythms; adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; adrenohypophysis hypofunction; functional or psychogenic amenorrhea; adrenohypophysis hyperfunction; migraine; hyperalgesia; pain; enhanced or  
5 exaggerated sensitivity to pain such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-polio syndrome and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; and tolerance to narcotics or withdrawal from narcotics.

10 The invention also provides a method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.

The invention also provides a compound of formula (I), or a pharmaceutically acceptable  
15 derivative thereof, for use in the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

A further aspect of the invention is the use of N-[2-(7-chloro-quinolin-4-ylamino)ethyl]-N-methyl-phthalamic acid or N-methyl-n-[2-napthalen-2-ylaminoethyl]benzamide for use in the treatment of diseases or disorders where an antagonist of a human orexin receptor is required such  
20 as those described above.

The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

The invention further provides for the use of N-[2-(7-chloro-quinolin-4-ylamino)ethyl]-  
25 N-methyl-phthalamic acid or N-methyl-n-[2-napthalen-2-ylaminoethyl]benzamide, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human orexin receptor is required.

For use in therapy the compounds of the invention are usually administered as a  
30 pharmaceutical composition. The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered by any convenient method, e.g. by oral, parenteral, buccal, sublingual, nasal, rectal or  
35 transdermal administration, and the pharmaceutical compositions adapted accordingly.

The compounds of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as liquids or solids, e.g. as syrups, suspensions, emulsions, tablets, capsules or lozenges.

A liquid formulation will generally consist of a suspension or solution of the active ingredient in a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

- 5 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose and cellulose.

- 10 A composition in the form of a capsule can be prepared using routine encapsulation procedures, e.g. pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), e.g. aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

- 15 Typical parenteral compositions consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

- 20 Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active ingredient in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a disposable dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas e.g. air, or an organic propellant such as a fluorochloro-
- 25 hydrocarbon or hydrofluorocarbon. Aerosol dosage forms can also take the form of pump-atomisers.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles where the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

- 30 Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

Compositions suitable for transdermal administration include ointments, gels and patches. Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.

- 35 The dose of the compound of formula (I), or a pharmaceutically acceptable derivative thereof, used in the treatment or prophylaxis of the abovementioned disorders or diseases will vary in the usual way with the particular disorder or disease being treated, the weight of the subject and other similar factors. However, as a general rule, suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 500 mg. Unit doses may be administered more than once a day for example two or

three times a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months. In the case of pharmaceutically acceptable derivatives the above figures are calculated as the parent compound of formula (I).

No toxicological effects are indicated/expected when a compound of formula (I) is administered in the above mentioned dosage range.

Human orexin-A has the amino acid sequence:

pyroGlu Pro Leu Pro Asp Cys Cys Arg Gln Lys Thr Cys Ser Cys Arg Leu

1                      5                      10                      15

Tyr Glu Leu Leu His Gly Ala Gly Asn His Ala Ala Gly Ile Leu Thr

10                      20                      25                      30

Leu-NH<sub>2</sub>

Orexin-A can be employed in screening procedures for compounds which inhibit the ligand's activation of the orexin-1 receptor.

In general, such screening procedures involve providing appropriate cells which express the orexin-1 receptor on their surface. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. In particular, a polynucleotide encoding the orexin-1 receptor is used to transfect cells to express the receptor. The expressed receptor is then contacted with a test compound and an orexin-1 receptor ligand to observe inhibition of a functional response. One such screening procedure involves the use of melanophores which are transfected to express the orexin-1 receptor, as described in WO 92/01810.

Another screening procedure involves introducing RNA encoding the orexin-1 receptor into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes are then contacted with a receptor ligand and a test compound, followed by detection of inhibition of a signal in the case of screening for compounds which are thought to inhibit activation of the receptor by the ligand.

Another method involves screening for compounds which inhibit activation of the receptor by determining inhibition of binding of a labelled orexin-1 receptor ligand to cells which have the receptor on their surface. This method involves transfecting a eukaryotic cell with DNA encoding the orexin-1 receptor such that the cell expresses the receptor on its surface and contacting the cell or cell membrane preparation with a compound in the presence of a labelled form of an orexin-1 receptor ligand. The ligand may contain a radioactive label. The amount of labelled ligand bound to the receptors is measured, e.g. by measuring radioactivity.

Yet another screening technique involves the use of FLIPR equipment for high throughput screening of test compounds that inhibit mobilisation of intracellular calcium ions, or other ions, by affecting the interaction of an orexin-1 receptor ligand with the orexin-1 receptor.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following Examples illustrate the preparation of pharmacologically active compounds of the invention. The Descriptions D1-D11 illustrate the preparation of intermediates to compounds of the invention.

In the Examples  $^1\text{H}$  NMR's were measured at 250MHz in  $\text{CDCl}_3$  unless otherwise stated.

5 The following abbreviations are used herein;

HATU means O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate

DMF means N,N-dimethyl formamide

10 **Description 1: [2-(6,7-Difluoro-quinoxalin-2-ylamino)-ethyl]-methyl-carbamic acid dimethyl-ethyl ester**

A mixture of (2-amino-ethyl)-methyl-carbamic acid dimethyl-ethyl ester (1.01g, 5.8mmol), 2-chloro-6,7-difluoro-quinoxaline (1.00g, 5.8mmol) and N,N-diisopropylethylamine (3.02ml, 17.4mmol) in xylene (10ml) was heated under argon at 80°C for 18h. The cooled reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water, brine, dried ( $\text{MgSO}_4$ ) and the solvent removed *in vacuo*. The residue was triturated with diethyl ether/pentane to afford the title compound as a pale orange solid.

15 Mass spectrum ( $\text{API}^+$ ): Found 339 ( $\text{MH}^+$ ).  $\text{C}_{16}\text{H}_{20}\text{F}_2\text{N}_4\text{O}_2$  requires 338.

20 **Description 2: N-(6,7-Difluoro-quinoxalin-2-yl)-N'-methyl-ethane-1,2-diamine dihydrochloride**

An ice-cooled solution of [2-(6,7-difluoro-quinoxalin-2-ylamino)-ethyl]-methyl-carbamic acid dimethyl-ethyl ester, D1 (500mg, 1.48mmol) in methanol (20ml) was treated with HCl in dioxane (4M solution, 4ml). After stirring under argon at room temperature for 4h the volatiles were removed *in vacuo* and the residue was triturated with diethyl ether to afford the title compound as a beige powder (100%).

25  $^1\text{H}$  NMR  $\delta$ : ( $\text{D}_6$ -DMSO) 2.51 (3H, s), 3.18 (2H, m), 3.69 (2H, m), 7.60 (1H, m), 7.87 (1H, m), 8.32 (1H, bs), 8.38 (1H, s), 8.98 (1H, bs).

30 **Description 3: Methyl-[2-(2,2,2-trifluoro-ethanoylamino)-ethyl]-carbamic acid dimethyl-ethyl ester**

Trifluoroacetic anhydride (2.23ml, 15.8mmol) was added drop-wise to an ice-cooled stirring solution of (2-amino-ethyl)-methyl-carbamic acid dimethyl-ethyl ester (2.5g, 14.4mmol) and triethylamine (2.4ml, 17.2mmol) in dichloromethane (80ml) under argon. After stirring for 1h, the ice-bath was removed and stirring continued for a further 72h. The reaction mixture was diluted with dichloromethane, washed with aqueous sodium bicarbonate solution, dried ( $\text{MgSO}_4$ ) and the solvent removed *in vacuo* to afford the title compound as a colourless gum (3.61g, 93%).

35 Mass spectrum ( $\text{API}^+$ ): Found 269 (M-H).  $\text{C}_{10}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_3$  requires 270.

40 **Description 4: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl-[2-(2,2,2-trifluoro-ethanoylamino)-ethyl]-amide**

An ice-cooled solution of methyl-[2-(2,2,2-trifluoro-ethanoylamino)-ethyl]-carbamic acid dimethyl-ethyl ester, D3 (3.61g, 13.4mmol) in dichloromethane (80ml) was treated with trifluoroacetic acid

- (20ml). After stirring at room temperature for 5h the mixture was poured cautiously onto solid  $K_2CO_3$  (excess)/ice. The product was extracted with dichloromethane (4X) then 10% methanol-dichloromethane (5X). The combined organics were dried ( $MgSO_4$ ) and the solvent removed *in vacuo*. The resulting yellow gum (380mg) was added to a stirring solution of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (530mg, 2.2mmol), *N,N*-diisopropylethylamine (1.17ml, 6.7mmol) and HATU (851mg, 2.2mmol). The reaction mixture was stirred at room temperature, under argon for 16h, then partitioned between ethyl acetate and water. The organic phase was washed with water (2X), brine, dried ( $MgSO_4$ ) and the solvent removed *in vacuo*. Chromatography (silica gel, 20-100% ethyl acetate-pentane) afforded the title compound as a colourless gum (443mg).
- Mass spectrum ( $API^+$ ): Found 390 ( $MH^+$ ).  $C_{16}H_{15}F_4N_3O_2S$  requires 389.

**Description 5: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (2-amino-ethyl)-methyl-amide**

- A solution of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl-[2-(2,2,2-trifluoro-ethanoylamino)-ethyl]-amide, D4 (443mg, 1.14mmol) in methanol/water (30ml/10ml) was treated with solid  $K_2CO_3$  (787mg, 5.70mmol) and stirred at room temperature, under argon for 16h. The methanol was removed *in vacuo*. The residue was diluted with water and extracted with ethyl acetate (3X). The combined organics were dried ( $MgSO_4$ ) and the solvent removed *in vacuo* to afford the title compound as a yellow gum (240mg, 72%).
- Mass spectrum ( $API^+$ ): Found 294 ( $MH^+$ ).  $C_{14}H_{16}FN_3OS$  requires 293.

**Description 6: (R,S)-(2-Amino-propyl)-carbamic acid *tert*-butyl ester**

- A solution of di-*tert*-butyl dicarbonate (13.9g, 0.064mol) in 1,4-dioxane (100 ml) was added dropwise to a stirring solution of (R,S)-propane-1,2-diamine (37.4g, 0.51mol) in 1,4-dioxane (200ml). After stirring at room temperature, under argon for 16 h the volatiles were removed *in vacuo*. The residue was dissolved in water and the resulting solution extracted with MDC (3X). The combined organics were dried ( $MgSO_4$ ) and the solvent removed *in vacuo* to afford the title compound as a yellow oil (11.1 g, 100%).
- Mass Spectrum ( $API^+$ ): Found 175 ( $MH^+$ ).  $C_8H_{18}N_2O_2$  requires 174.
- $^1H$  NMR  $\delta$ : 1.07 (3H, d,  $J = 6Hz$ ), 1.29 (2H,bs), 1.44 (9H, s), 2.80-3.20 (3H, bm), 5.56 (1H,bt).

**Description 7: (R,S)-[2-(3,4-dimethoxy-benzylamino)-propyl]-carbamic acid *tert*-butyl ester**

- A stirring solution of (R,S)-(2-amino-propyl)-carbamic acid *tert*-butyl ester, D6 (3.28g, 18.9mmol) and 3,4-dimethoxy-benzaldehyde (3.15g, 18.9mmol) in 1,2-dichloro-ethane (75ml) was treated with sodium triacetoxyborohydride (6.02g, 28.4mmol) added portionwise. After stirring at room temperature, under argon for 16h the reaction mixture was diluted with dichloromethane and washed with saturated  $K_2CO_3$  solution. The organic phase was dried ( $MgSO_4$ ) and the solvent removed *in vacuo*. Chromatography (silica gel, 0-100% pentane-ethyl acetate) afforded the title compound as an orange gum (4.12g, 67%).
- Mass Spectrum ( $API^+$ ): Found ( $MH^+$ )323.  $C_{17}H_{28}N_2O_4$  requires 324.

**Description 8: (R,S)-[2-((3,4-Dimethoxy-benzyl)-{1-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanoyl}-amino)-propyl]-carbamic acid *tert*-butyl ester**

A solution of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (200mg, 0.84mmol) in DMF (20ml) was treated sequentially with *N,N*-diisopropylethylamine (0.44ml, excess), HATU (320 mg, 2.52mmol) then after 15 min. (R,S)-[2-(3,4-dimethoxy-benzylamino)-propyl]-carbamic acid *tert*-butyl ester, D7 (272mg, 0.84mmol). The reaction mixture was stirred at room temperature, under argon for 16h then partitioned between ethyl acetate and water. The organic phase was washed with water (3X), brine, dried (MgSO<sub>4</sub>) and the solvent removed *in vacuo* to afford the title compound as a yellow gum (456mg, 100%).

10 Mass Spectrum (API<sup>+</sup>): Found (MH<sup>+</sup>)544. C<sub>28</sub>H<sub>34</sub>FN<sub>3</sub>O<sub>5</sub>S requires 543.

**Description 9: (R,S)-5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (2-amino-1-methyl-ethyl)-(3,4-dimethoxy-benzyl)-amide**

15 An ice-cooled solution of (R,S)-[2-((3,4-dimethoxy-benzyl)-{1-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanoyl}-amino)-propyl]-carbamic acid *tert*-butyl ester, D8, (430mg, 0.79mmol) in dichloromethane (22.5ml) was treated with trifluoroacetic acid (2.5ml). After stirring at room temperature for 5h the mixture was poured cautiously onto solid K<sub>2</sub>CO<sub>3</sub> (excess)/ice. The product was extracted with dichloromethane (3X), the combined organics were dried (MgSO<sub>4</sub>) and the solvent removed *in vacuo* to afford the title compound as a brown gum (100%).

20 Mass Spectrum (API<sup>+</sup>): Found (MH<sup>+</sup>)444. C<sub>23</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>3</sub>S requires 443.

**Description 10: [2-(5-Bromo-pyrimidin-2-ylamino)-ethyl]-methyl-carbamic acid dimethyl-ethyl ester**

25 The title compound (2.40g, 73%) was prepared from (2-amino-ethyl)-methyl-carbamic acid dimethyl-ethyl ester (1.74g, 10mmol), 2-chloro-5-bromo-pyrimidine (1.93g, 10mmol), *N,N*-diisopropylethylamine (3.87g, 30mmol) and K<sub>2</sub>CO<sub>3</sub> (2.76g, 20mmol) according to the procedure described for Description 1.

Mass spectrum (API<sup>+</sup>): Found 230 (M-<sup>1</sup>BOC). C<sub>12</sub>H<sub>19</sub><sup>79</sup>BrN<sub>4</sub>O<sub>2</sub> requires 330.

**Description 11: *N*-(5-bromo-pyrimidin-2-yl)-*N'*-methyl-ethane-1,2-diamine**

30 An ice-cooled solution of [2-(5-bromo-pyrimidin-2-ylamino)-ethyl]-methyl-carbamic acid dimethyl-ethyl ester, D10 (2.32g, 7.0mmol) in dichloromethane (90ml) was treated with trifluoroacetic acid (10ml). The reaction mixture was stirred for 2h at room temperature, under argon then poured onto K<sub>2</sub>CO<sub>3</sub> (excess)/ice. The aqueous layer was separated, washed with dichloromethane (3X) and the combined organics dried (MgSO<sub>4</sub>) and the solvent removed *in vacuo* to afford the title compound (1.00g, 61%).

35 Mass Spectrum (API<sup>+</sup>): Found (MH<sup>+</sup>)231. C<sub>7</sub>H<sub>11</sub><sup>79</sup>BrN<sub>4</sub> requires 230.

**Example 1: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid [2-(6,7-difluoro-quinoxalin-2-ylamino)-ethyl]-methyl-amide**

40 A solution of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (50mg, 0.21mmol) in DMF (3ml) was treated sequentially with *N,N*-diisopropylethylamine (0.20ml, excess), HATU (79mg,

0.21mmol) then after 15 min. *N*-(6,7-difluoro-quinoxalin-2-yl)-*N'*-methyl-ethane-1,2-diamine.dihydrochloride, D2 (65mg, 0.21mmol). The reaction mixture was stirred at room temperature, under argon for 72h then partitioned between diethyl ether and water. The organic phase was washed with water (3X), brine, dried (MgSO<sub>4</sub>) and the solvent removed *in vacuo*. The residue was triturated with pentane to afford the title compound as a pale yellow powder (38mg, 40%).

Mass spectrum (Electrospray LC/MS): Found (MH<sup>+</sup>) 458. C<sub>22</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>OS requires 457.

**Example 2: 4-(4-Fluoro-phenyl)-1-methyl-1*H*-pyrazole-3-carboxylic acid [2-(6,7-difluoro-quinoxalin-2-ylamino)-ethyl]-methyl-amide**

The title compound was prepared from 4-(4-fluoro-phenyl)-1-methyl-1*H*-pyrazole-3-carboxylic acid (46mg, 0.21mmol) and *N*-(6,7-difluoro-quinoxalin-2-yl)-*N'*-methyl-ethane-1,2-diamine.dihydrochloride, D2 (65mg, 0.21mmol) according to the procedure described for Example 1, as a yellow solid (65mg, 71%).

Mass spectrum (Electrospray LC/MS): Found (MH<sup>+</sup>) 441. C<sub>22</sub>H<sub>19</sub>F<sub>3</sub>N<sub>6</sub>O requires 440.

**Example 3: 4-(4-Fluoro-phenyl)-1*H*-pyrazole-3-carboxylic acid [2-(6,7-difluoro-quinoxalin-2-ylamino)-ethyl]-methyl-amide**

The title compound was prepared from 4-(4-fluoro-phenyl)-1*H*-pyrazole-3-carboxylic acid (43mg, 0.21mmol) and *N*-(6,7-difluoro-quinoxalin-2-yl)-*N'*-methyl-ethane-1,2-diamine.dihydrochloride, D2 (65mg, 0.21mmol) according to the procedure described for Example 1, as a yellow solid (65mg, 71%).

Mass spectrum (Electrospray LC/MS): Found (MH<sup>+</sup>) 427. C<sub>21</sub>H<sub>17</sub>F<sub>3</sub>N<sub>6</sub>O requires 426.

**Example 4: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid [2-(benzoxazol-2-ylamino)-ethyl]-amide**

A solution of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (2-amino-ethyl)-methyl-amide, D5 (120mg, 0.41mmol) in THF (7ml) was treated with triethylamine (0.057ml) and 2-chlorobenzoxazole (0.047ml, 0.41mmol). The reaction mixture was stirred at room temperature, under argon for 16h then the volatiles removed *in vacuo*. The residue was chromatographed (silica gel, 25% ethyl acetate-pentane) to afford the title compound as a white solid (97mg, 58%).

Mass spectrum (Electrospray LC/MS): Found (MH<sup>+</sup>) 411. C<sub>21</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>S requires 410.

**Example 5: (R,S)-5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid [2-(benzoxazol-2-ylamino)-1-methyl-ethyl]-(3,4-dimethoxy-benzyl)-amide**

The title compound was prepared from (R,S)-5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (2-amino-1-methyl-ethyl)-(3,4-dimethoxy-benzyl)-amide, D9 (380mg, 0.86mmol) and 2-chlorobenzoxazole (0.098ml, 0.86mmol), according to the procedure described for Example 4, as a white foam (150mg, 31%).

Mass spectrum (Electrospray LC/MS): Found (MH<sup>+</sup>) 561. C<sub>30</sub>H<sub>29</sub>FN<sub>4</sub>O<sub>4</sub>S requires 560.



**Example 6: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid [2-(5-bromo-pyrimidin-2-ylamino)-ethyl]-methyl-amide**

The title compound was prepared from 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (78mg, 0.33mmol) and *N*-(5-bromo-pyrimidin-2-yl)-*N'*-methyl-ethane-1,2-diamine, D11 (76mg, 0.33mmol), according to the procedure described for Example 1, as a solid (105mg, 71%).  
Mass spectrum (Electrospray LC/MS): Found ( $MH^+$ ) 450.  $C_{18}H_{17}^{79}BrFN_3OS$  requires 449.

It is to be understood that the present invention covers all combinations of particular and preferred subgroups described herein above.

**Determination of Orexin-1 Receptor Antagonist Activity**

The orexin-1 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

**Experimental Method**

HEK293 cells expressing the human orexin-1 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GIBCO BRL and 10% heat inactivated fetal calf serum from Gibco BRL. The cells were seeded at 20,000 cells/100  $\mu$ l/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10  $\mu$ g/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37°C in 5% CO<sub>2</sub>.

Agonists were prepared as 1 mM stocks in water:DMSO (1:1). EC<sub>50</sub> values (the concentration required to produce 50% maximal response) were estimated using 11x half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, 10mM glucose, 2.5 mM KCl, 1.5 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub> and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%). Antagonist IC<sub>50</sub> values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 3.0 nM human orexin-A using 11x half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.

On the day of assay 50  $\mu$ l of cell medium containing probenecid (Sigma) and Fluo3AM (Texas Fluorescence Laboratories) was added (Quadra, Tomtec) to each well to give final concentrations of 2.5 mM and 4  $\mu$ M, respectively. The 96-well plates were incubated for 90 min at 37°C in 5% CO<sub>2</sub>. The loading solution containing dye was then aspirated and cells were washed with 4x150  $\mu$ l Tyrode's buffer containing probenecid and 0.1% gelatin (Denley Cell Wash). The volume of buffer left in each well was 125  $\mu$ l. Antagonist or buffer (25  $\mu$ l) was added (Quadra) the cell plates gently shaken and incubated at 37°C in 5% CO<sub>2</sub> for 30 min. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument and maintained at 37°C in humidified air. Prior to drug addition a single image of the cell plate was

taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 sec (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this figure. The peak increase in fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter logistic fit (as described by Bowen and Jerman, *TIPS*, 1995, 16, 413-417) to generate a concentration effect value. Antagonist  $K_b$  values were calculated using the equation:

$$K_b = IC_{50} / (1 + ([3/EC_{50}]))$$

where  $EC_{50}$  was the potency of human orexin-A determined in the assay (in nM terms) and  $IC_{50}$  is expressed in molar terms.

Compounds of Examples tested according to this method had  $pK_b$  values 6.4 to 7.4 at the human cloned orexin-1 receptor.

The orexin-2 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

#### Experimental Method

CHO-DG44 cells expressing the human orexin-2 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GIBCO BRL and 10% heat inactivated fetal calf serum from Gibco BRL. The cells were seeded at 20,000 cells/100  $\mu$ L/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10  $\mu$ g/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37°C in 5%  $CO_2$ .

Agonists were prepared as 1 mM stocks in water:DMSO (1:1).  $EC_{50}$  values (the concentration required to produce 50% maximal response) were estimated using 11x half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, 10mM glucose, 2.5 mM KCl, 1.5 mM  $CaCl_2$ , 1.2 mM  $MgCl_2$  and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%). Antagonist  $IC_{50}$  values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 10.0 nM human orexin-A using 11x half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.

On the day of assay 50  $\mu$ L of cell medium containing probenecid (Sigma) and Fluo3AM (Texas Fluorescence Laboratories) was added (Quadra, Tomtec) to each well to give final concentrations of 2.5 mM and 4  $\mu$ M, respectively. The 96-well plates were incubated for 60 min at 37°C in 5%  $CO_2$ . The loading solution containing dye was then aspirated and cells were washed with 4x150  $\mu$ L Tyrode's buffer containing probenecid and 0.1% gelatin (Denley Cell Wash). The volume of buffer left in each well was 125  $\mu$ L. Antagonist or buffer (25  $\mu$ L) was added (Quadra) the

cell plates gently shaken and incubated at 37C in 5% CO<sub>2</sub> for 30 min. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument. Prior to drug addition a single image of the cell plate was taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24  
5 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 sec (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this figure. The peak increase in fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter logistic fit (as described by Bowen and Jerman, *TiPS*, 1995, 16, 413-417) to generate a  
10 concentration effect value. Antagonist Kb values were calculated using the equation:

$$K_b = IC_{50} / (1 + ([3/EC_{50}]))$$


where EC<sub>50</sub> was the potency of human orexin-A determined in the assay (in nM terms) and IC<sub>50</sub> is expressed in molar terms.

Compounds of Examples tested according to this method had pK<sub>b</sub> values in the range <6.6  
15 to 7.4 at the human cloned orexin-2 receptor.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of  
20 product, composition, process, or use claims and may include, by way of example and without limitation the following claims:

## CLAIMS

1. A compound of formula (I):



(I)

wherein:

R represents an optionally substituted (C<sub>1-4</sub>)alkyl;

Y represents hydrogen or an optionally substituted (C<sub>1-4</sub>)alkyl.

- 10 Het represents an optionally substituted 5- or 6- membered heteroaryl group containing up to 3 heteroatoms selected from N, O, and S, or an optionally substituted bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S;

- 15 Ar represents a phenyl or a 5- or 6-membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R<sup>3</sup>, and further optional substituents; or Ar represents an optionally substituted bicyclic aromatic or heteroaromatic group containing up to 3 heteroatoms selected from N, O and S;

- 20 R<sup>3</sup> independently represents hydrogen, an optionally substituted (C<sub>1-4</sub>)alkoxy, halo, optionally substituted (C<sub>1-6</sub>)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 3 heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt thereof, provided the compound is not N-[2-(7-chloro-quinolin-4-ylamino)ethyl]-N-methyl-phthalamic acid; or N-methyl-n-[2-napthalen-2-ylaminoethyl]benzamide.

- 25 2. A compound according to claim 1 wherein Het represents pyrimidinyl, benzoxazolyl or quinoxalinyl.

3. A compound according to claim 1 or 2 wherein Ar represents an optionally substituted thiazolyl or pyrazolyl.

- 30 4. A compound according to any one of claims 1 to 3 wherein R<sup>3</sup> represents an optionally substituted phenyl.

5. The compound of any one of Examples 1 to 6 or a pharmaceutically acceptable salt of any one thereof.

35

6. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 5 7. A method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof.

## INTERNATIONAL SEARCH REPORT

International application No

PCT/65 02/05665

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D417/12 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 098363 A (IATSIMIRSKAIA EUGENIA A ;PADERES GENEVIEVE D (US); RAJAPAKSE RANJA) 12 December 2002 (2002-12-12) claims 24-26; example B148 ---	1,2,6
X	WO 01 23357 A (AMGEN INC) 5 April 2001 (2001-04-05) example 68, step "A" claims 7,8; example 68 ---	1,6
X	WO 97 24124 A (SMITHKLINE BEECHAM CORP ;ALI FADIA E (US); BONDINELL WILLIAM E (US) 10 July 1997 (1997-07-10) claim 9, last but one compound and one before; claim 10, 1st and 7th compound claim 11 --- -/-	1,6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

18 February 2003

Date of mailing of the international search report

26/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Schmid, A

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB 02/05665

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 008 230 A (OKU TERUO ET AL) 28 December 1999 (1999-12-28) example 93(4) ---	1,6
X	WO 92 07844 A (PFIZER) 14 May 1992 (1992-05-14) example 104 ---	1,6
X	WO 91 18904 A (AMERICAN HOME PROD) 12 December 1991 (1991-12-12) example 6 ---	1,6
A	WO 00 47577 A (COULTON STEVEN ; JOHNS AMANDA (GB); PORTER RODERICK ALAN (GB); SMIT) 17 August 2000 (2000-08-17) cited in the application page 35, line 3 -page 35, line 43; claims 1-13; examples 1-81 ---	1-7
A	WO 00 47576 A (JOHNS AMANDA ; PORTER RODERICK ALAN (GB); SMITHKLINE BEECHAM PLC (G) 17 August 2000 (2000-08-17) cited in the application page 21, line 9 -page 22, line 9; claims; examples 1-22 -----	1-7

# INTERNATIONAL SEARCH REPORT

Inter application No.  
PCT/GB 02/05665

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 7 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

Internat<sup>n</sup> Application No

PCT/GB 02/05665

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 02098363	A	12-12-2002	WO	02098363 A2	12-12-2002
WO 0123357	A	05-04-2001	AU	7722000 A	30-04-2001
			EP	1216230 A2	26-06-2002
			WO	0123357 A2	05-04-2001
			US	6514964 B1	04-02-2003
WO 9724124	A	10-07-1997	AU	1295597 A	28-07-1997
			BR	9612381 A	13-07-1999
			CN	1209063 A	24-02-1999
			CZ	9802038 A3	17-03-1999
			EP	0906103 A1	07-04-1999
			JP	2000502704 T	07-03-2000
			NO	983001 A	26-08-1998
			PL	327626 A1	21-12-1998
			TR	9801254 T2	21-10-1998
			US	6159964 A	12-12-2000
			WO	9724124 A1	10-07-1997
			ZA	9610854 A	02-04-1998
US 6008230	A	28-12-1999	AU	7228896 A	07-05-1997
			EP	0876345 A1	11-11-1998
			WO	9714681 A1	24-04-1997
			JP	11514361 T	07-12-1999
WO 9207844	A	14-05-1992	AT	124694 T	15-07-1995
			AU	644035 B2	02-12-1993
			AU	9059291 A	26-05-1992
			BR	9107070 A	31-05-1994
			CA	2095213 A1	07-05-1992
			CN	1061411 A	27-05-1992
			CZ	9204009 A3	15-12-1993
			DE	9190155 U1	07-10-1993
			DE	69111077 D1	10-08-1995
			DE	69111077 T2	02-11-1995
			DK	556310 T3	21-08-1995
			EP	0556310 A1	25-08-1993
			ES	2074867 T3	16-09-1995
			FI	932032 A	05-05-1993
			GR	3017122 T3	30-11-1995
			HU	64533 A2	28-01-1994
			IE	913854 A1	22-05-1992
			JP	5507290 T	21-10-1993
			MX	9101913 A1	08-07-1992
			NO	931635 A	05-05-1993
			NZ	240476 A	27-04-1994
			PT	99415 A	30-09-1992
			SK	400992 A3	09-08-1995
			US	5444062 A	22-08-1995
			WO	9207844 A1	14-05-1992
			ZA	9108767 A	05-05-1993
WO 9118904	A	12-12-1991	AU	7997091 A	31-12-1991
			JP	5507702 T	04-11-1993
			WO	9118904 A1	12-12-1991
			US	5149700 A	22-09-1992
WO 0047577	A	17-08-2000	AU	2804400 A	29-08-2000

## INTERNATIONAL SEARCH REPORT

Internati pplication No  
PCT/GB 02/05665

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0047577 A		WO 0047577 A1 EP 1150977 A1 JP 2002536445 T	17-08-2000 07-11-2001 29-10-2002
WO 0047576 A	17-08-2000	WO 0047576 A1	17-08-2000